Prospective Clinical Trial to Assess the Efficacy and Safety of EPOGAM 1000 in Patients With Atopic Dermatitis (Explorative Pilot Study)

NCT00878670 Phase 4 COMPLETED

In this study it will be investigated if patients with atopic dermatitis responding to EPOGAM treatment, show a significant increase of dihomo-gamma-linolic acid in the blood.

Details

Lead sponsor	Max Zeller Soehne AG
Phase	Phase 4
Status	COMPLETED
Enrolment	23
Start date	2009-03
Completion	2010-10

Conditions

• Atopic Dermatitis
• Neurodermatitis

Interventions

• EPOGAM 1000

Primary outcomes

• Levels of dihomo-gamma linolic acid in the blood — 0, 4 and 12 weeks after start of treatment
• Efficacy of EPOGAM 1000 treatment on the symptoms of atopic dermatitis — 0, 4 and 12 weeks after start of treatment

Countries

Switzerland